News – Page 908 – Endpoints News

SIGN UP

From $30M launch round to $400M buyout deal — with $250M upfront — in 10 short months

6 years ago

Top 20 by revenue: New analysis highlights huge impact of tax reform on many — but not all — of the top pharma ...

6 years ago

Amgen swoops in with $13.4B deal to pluck blockbuster Otezla from Celgene

6 years ago

Olumiant from Lilly, Incyte clears third eczema study, but who will use it?

6 years ago

‘Absolute standout’ biopharma analyst Mark Schoenebaum has died

6 years ago

Pfizer, Astellas win priority review for Xtandi sNDA; Hemispherx changes its name

6 years ago

Ignyta founder boosts team at his new cancer startup; Cytomx CMO hits the exit

6 years ago

Why would Amgen want to buy Alexion? Analysts call hotly rumored takeover unlikely, but seize the moment

6 years ago

FDA asks why Novartis took two months to launch formal internal probe, after AveXis flagged data manipulation

6 years ago

Building on successful PD-1 pact, Eli Lilly licenses diabetes drug to Chinese partners at Innovent

6 years ago

Clearside Biomedical predicts its uveitis drug will be rejected, after FDA requests more data

6 years ago

GSK's Hal Barron heralds their second positive pivotal for crucial anti-BCMA therapy, pointing to a push for quick ...

6 years ago

Biotech leaders rally behind Chinese scientists in US, calls for 'measured' policies in wake of purges

6 years ago

Amgen, Allergan biosimilar of Roche's blockbuster Rituxan clears another US pivotal study

6 years ago

BeiGene and Mustang nail down special FDA status for top drugs; Roche bags added coverage for Hemlibra

6 years ago

Trump administration revives bid to get drug list prices on TV ads

6 years ago

Get as much Spravato as you can, Trump orders VA while suggesting J&J should offer it to veterans for free

6 years ago

An emboldened AstraZeneca splurges $95M on a priority review voucher. Where do they need the FDA to hustle up?

6 years ago

Versant-backed Chinook gets a $65M launch round for its discovery quest in a resurgent kidney field

6 years ago

Sir Andrew Dillon, NICE's first — and only — chief executive to step down next year

6 years ago

Eight weeks between each HIV treatment? GSK notches PhIII win as it chases OK for long-acting regimen

6 years ago

Prisoner #87850-053 does not get to add drug developer to his list of credits

6 years ago

Finch grabs a $53M round designed to take their ‘breakthrough’ microbiome treatment through a potentially pivotal ...

6 years ago

Vienna-based vaccine developer Themis signs pact with Merck for 'blockbuster indication'

6 years ago

First page Previous page 905 906 907908909 910 911 Next page Last page